Lisa R. Diller, MD
Clinical Director, Pediatric Oncology
Medical Director, Clinical Cancer and Blood Disorders Service Line
Medical Director, David B. Perini, Jr. Quality of Life Clinic
Professor of Pediatrics, Harvard Medical School
Centers/ProgramsPediatric Solid Tumors
Pediatric Cancer Survivorship
Pediatric Cancer Genetic Risk Program
Office phone: 617-632-5642
Preferred contact method: office phone
View Physician Profile
Late effects of pediatric cancer, Retinoblastoma, Solid tumors, Wilms tumor, Neuroblastoma, Cancer predisposition, Melanoma, Global health
Area of ResearchNeuroblastoma and Cancer Survivorship
Dana-Farber Cancer Institute
450 Brookline Avenue
Shields Warren 312
Boston, MA 02215
Dr. Lisa Diller is the Chief Medical Officer, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. As a pediatric oncologist and the Clinical Director of Pediatric Oncology, she leads the joint clinical Pediatric Oncology Program at the Dana-Farber Cancer Institute and Boston Children's Hospital. She is also the Director of the Perini Family Survivors Center and the David B. Perini, Jr. Quality of Life Clinic for Cancer Survivors at Dana-Farber. She is a Professor of Pediatrics at Harvard Medical School. Dr. Diller received a bachelors degree from Harvard University, and earned her medical degree from the University of California at San Diego. She was a resident at Boston Children's Hospital and did her subspecialty training at Boston Children's Hospital/Dana-Farber Institute where she has been on the faculty for more than 20 years. Dr. Diller's research focuses on the late effects of treatment for childhood cancer and genetic cancer predisposition syndromes in childhood. In addition, she investigates novel treatments for pediatric solid tumors, particularly tumors that occur in infants and toddlers.
- Stephen E. Sallan Leadership award, 2004
- Benacerraf-Frei Investigator, DFCI, 1998
- Dyson Scholar Award, DFCI, 1998
ResearchNeuroblastoma and Cancer Survivorship
The focus of our research is in two major areas: the treatment of patients with solid tumors - notably neuroblastoma and Wilms' tumor - and the study of survivors of childhood cancer.
In treating patients with neuroblastoma, our approach has been to intensify therapy using high-dose therapy in tandem with stem cell rescue. In addition, we are studying new approaches to the treatment of minimal residual neuroblastoma, including antiangiogenic agents, demethylating agents, and immunomodulatory approaches. (We are participants in the New Agents in Neuroblastoma Therapy consortium.) Studies of survivors of neuroblastoma are also under way.
In research on medical late effects, we have been studying young adult patients with a history of cancer treatment, hoping to delineate the morbidity of a variety of therapies and to introduce screening and prevention in this group of patients. We also have completed an early mammography trial after chest irradiation, showing that women who were treated with chest radiation are at significant risk of breast cancer and that mammography detects early tumors in this cohort. A prevention trial using tamoxifen for these women is in analysis.
Moreover, we are active participants in the largest childhood cancer survivor cohort study, the Childhood Cancer Survivor Study, involving 24 centers and over 17,000 survivors. We have completed an analysis of breast cancers in that cohort, and are studying risk factors for secondary sarcomas. Interventional studies using the same cohort are under way, including a web-based smoking cessation intervention, an analysis of breast cancer screening behaviors, and a planned study of renal disease screening.